Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-15

Clinical Trial Update: Docetaxel With or Without AZD6244 in Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel with or without the MEK inhibitor AZD6244 in melanoma has completed, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AZD6244 (selumetinib)
  • Taxotere (docetaxel)

Snippet

Sponsor: University of Oxford | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2024-08-15